• metastatic/advanced - colorectal cancer (mCRC) 2
• mCRC - (neo)adjuvant (NA)
• mCRC - 1st line (L1) 5
• mCRC - 2nd line (L2) 6
• endometrial cancer 10

 

• chemotherapy
• Standard of Care (SoC)
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus FOLFOXIRI plus bevacizumab
• durvalumab based treatment
• nivolumab based treatment
• nivolumab plus SoC
• pembrolizumab based treatment
• pembrolizumab alone

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs Bevacizumab plus FOLFOXIRI

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs Bevacizumab plus FOLFOXIRI; 
Risk of bias:  low;   some concerns;   high;  NA;